Oral clopidogrel for chronic central serous chorioretinopathy: A short-term preliminary study

To report the efficacy of oral clopidogrel for treatment of chronic and recurrent central serous chorioretinopathy (CSC). This is a retrospective uncontrolled case series. Fourteen eyes in 14 patients with the clinical and angiographic findings of chronic and recurrent CSC were enrolled. Clinical data including best-corrected visual acuity (BCVA), durations of symptoms, central retinal thickness (CRT) and macular volume measured on optical coherence tomography (OCT) were collected at baseline. Oral clopidogrel 75 mg daily was administrated at least for 2 weeks until the serous detachment resolved or no satisfactory result was obtained. OCT was performed monthly until the end of follow-up in all patients. Fluorescein angiography was repeated during the follow-up period in nine patients. There were eight eyes with chronic CSC and six with recurrent CSC. After clopidogrel treatment for mean 8.07 weeks (range, 2–24 weeks), the BCVA improved or stabilized in 12 of 14 eyes (85.7%) at the end of follow-up. Nine eyes (64.3%) attained a complete resolution of serous detachment, and four (28.6%) had improvement in subretinal fluid reabsorption on OCT. The CRT and macular volume were significantly decreased compared with baseline (234.14 ± 62.46 μm vs. 355.64 ± 108.05 μm, and 7.145 ± 0.618 μL vs. 7.916 ± 1.056 μL, respectively, p